Oxurion concludes enrollment of patients for THR-687 Phase 1 trial
Category: #health  By Nikita Chaurasia  Date: 2019-09-06
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Oxurion concludes enrollment of patients for THR-687 Phase 1 trial
  • 12 patients with DME have enrolled into the study.
     
  • The results for the Phase 1 trial will be out by the end of 2019.

Oxurion NV, a biopharmaceutical firm involved in the development of innovative treatments to preserve vision of diabetic eye disease patients, has recently announced that it has completed enrolling patients in the Phase 1 trial for the evaluation of THR-687.

Apparently, Phase 1 trial, a multicenter, open-label, dose-escalation study would be evaluating the safety of one intravitreal injection of THR-687’s escalating dose levels (3) for treating patients suffering from diabetic macula edema (DME). A total number of 12 patients with the disease have been enrolled in the study trial.

For the record, THR-687 is a new pan-RGD integrin antagonist that is being developed as a possible treatment for patients suffering from diabetic eye disease. According to the preclinical demonstration, THR-687 is capable of targeting several aspects of retinal vascular disease like inflammation, neovascularization and vessel leakage. Results for the Phase 1 evaluation are expected to be out by the end of 2019.

Oxurion NV’s CEO, Patrik De Haes, MD, commented that the conclusion of patient recruitment portion means that the company is on track to unveil the results from the Phase 1 study before 2019 ends. After the recent Phase 1 with THR-149 exhibited positive results the company has been looking forward to its first THR-687 clinical data read-out which is the second VEGF pathway and independent molecule in the company’s innovative pipeline primarily focused on DME.

About the Oxurion:

Headquartered in Belgium, Oxurion focuses on developing treatments for diseases affecting the backside of the eye in patients. The company has engineered a diverse portfolio of drug candidates capable of modifying diseases that also include the treatment for diabetic eye disease, the main cause of blindness among working-age people around the world. It owns the global rights to Jetrea, also known as ocriplasmin, which is the only pharmacological vitreolysis drug to get approval for the treatment of symptomatic vitreomacular adhesion in the U.S.

 

Source Credit- https://www.oxurion.com/content/oxurion-completes-enrollment-phase-1-clinical-trial-evaluating-thr-687-novel-pan-rgd

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Nokia partners with LG Uplus to expand 5G coverage in South Korea

Nokia partners with LG Uplus to expand 5G coverage in South Korea

By Nikita Chaurasia

Finnish telecommunications giant Nokia Corporation has reportedly signed a joint venture agreement with LG Uplus, a prominent cellular carrier, to expand 5G coverage in South Korea. The duo intends to achieve this by deploying Nokia’s end-to-e...

Mercedes-Benz unveils the S-Class of EVs, comes with a 56-inch display

Mercedes-Benz unveils the S-Class of EVs, comes with a 56-inch display

By Nikita Chaurasia

Mercedes-Benz, a German multinational automaker of luxury and commercial vehicles, has unveiled its flagship electric sedan, the EQS. The new vehicle is likely to allow Mercedes to take on Tesla Inc., as the market for electric vehicles (EVs) continu...

Ford takes on GM, Tesla by debuting its first hands-free driving system

Ford takes on GM, Tesla by debuting its first hands-free driving system

By Nikita Chaurasia

Ford Motor Company, the American multinational automaker, is reportedly planning on introducing a hands-free driving feature on its 2021 Mustang Models as well as 2021 F-150 pickup truck through a software update, by the end of the year. The automob...